Kaitlyn D’Onofrio

DocwireNews

Intravitreal-administered anti-vascular endothelial growth factor&nbsp;(VEGF) agents have changed the treatment paradigm for patients with wet age-related macular degeneration (AMD), but&nbsp;real-world evidence shows patients lose visual acuity over time due to a high treatment&nbsp;burden. In addition, some patients who are treated with maximum therapy still have&nbsp;active disease and fluid. The recently approved anti-VEGF&nbsp;brolucizumab is indicated for wet AMD. A study found that brolucizumab effectively controls wet AMD disease&nbsp;activity, as well as decreases the treatment burden by extended treatment interval. The results of the study were published as part of the American Society of Retina Specialists 2020 Virtual Annual Meeting.This multicenter, real-world, retrospective study evaluated the safety and efficacy of brolucizumab and included both treatment-nai&#776;ve patients (n=21; 7.4%) and those who switched to brolucizumab from other anti-VEGF agents (n=263; 92.6%).A majority of patients were female (n=166; 58.9%), and the mean patient age was 81.2 years (range, 51-99 years). The most common reason for switching to brolucizumab was persistent fluid (n=168; 63.9%). Patients received a mean 2.4 brolucizumab injections (range, 1-8 injections).About half of patients discontinued brolucizumab (n=147; 54.4%), most commonly out of caution following reports of intraocular inflammation (n=129; 86%). Twelve patients (8%) discontinued due to adverse events (AEs). Fourteen total AEs occurred, including uveitis (n=10; 3.7%), pain (n=3; 1.1%), and occlusive vasculitis (n=1; 0.37%).Patients who received at least three brolucizumab injections saw improvements across multiple measures, including the proportion of patients with no intraretinal fluid, subretinal fluid, or pigment epithelial detachment (PED); measurements of central retinal thickness&nbsp;and PED height; and Early Treatment Diabetic Retinopathy Study Letters score.London NJS, Khanani AM, Thompson MM, et al. Treating Neovascular AMD Patients with Brolucizumab: A Real-World Study. Presented during the ASRS 2020 Virtual Annual Meeting, July 24-26, 2020.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Study Assesses Efficacy of Brolucizumab for Wet AMD

ASRS 2020

Intravitreal-administered anti-vascular endothelial growth factor (VEGF) agents have changed the treatment paradigm for patients with wet age-related macular degeneration ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe